Inhaled Budesonide Commonly Used to Treat Asthma Significantly Reduces Need for Hospitalization in COVID-19 Patients

Budesonide is a corticosteroid used in the long-term management of asthma and chronic obstructive pulmonary disease (COPD).

The findings from the Phase 2 randomized study that involved 146 people - out of whom half took 800 micrograms of the medication twice a day and half were on usual care - suggest that inhaled budesonide reduced the relative risk of requiring urgent care or hospitalisation by 90% in the 28-day study period. Participants allocated the budesonide inhaler also had a quicker resolution of fever, symptoms and fewer persistent symptoms after 28 days. The study also demonstrated that there was a reduction in persistent symptoms in those who received budesonide.

“There have been important breakthroughs in hospitalized COVID-19 patients, but equally important is treating early disease to prevent clinical deterioration and the need for urgent care and hospitalization, especially to the billions of people worldwide who have limited access to hospital care,” said Professor Mona Bafadhel of the University’s Nuffield Department of Medicine, who led the trial. “The vaccine programs are really exciting, but we know that these will take some time to reach everyone across the world. I am heartened that a relatively safe, widely available and well studied medicine such as an inhaled steroid could have an impact on the pressures we are experiencing during the pandemic.”

“Although not the primary outcome of study, this is an important finding,” said Prof Bafadhel, a Respiratory Consultant working at the Oxford University Hospitals NHS Foundation Trust. “I am encouraged to see the reduction in persistent symptoms at 14 and 28 days after treatment with budesonide. Persistent symptoms after the initial COVID-19 illness have emerged as a long-term problem. Any intervention which could address this would be a major step forward.”

Related Links:
University of Oxford